Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033398373> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2033398373 endingPage "A619" @default.
- W2033398373 startingPage "A619" @default.
- W2033398373 abstract "Explore differences/similarities in epidemiology and drug treatment of metastatic breast cancer (MBC) in EU5. All data was derived from the Kantar Health CancerMPact database, sources for which include country specific cancer registries, published scientific studies and proprietary physician surveys comprising 85 doctors seeing 9,255 patients per month. Age and gender specific incidence rates, annual stage specific progression rates and annual stage specific survival rates are used to calculate total number of surviving patients at a specific stage up to 10 years after diagnosis. Prevalence of BC ranged between 41-73 per 100K population across EU-5. Among BC patients, prevalence of MBC was similar: 8% (UK, Italy) to 10% (Germany, France, Spain). Overall 62% of MBC patients were diagnosed with HER2-negative disease (56% Germany-70% France). Among these patients 35-40% had active disease and were treated with chemotherapy. Patients with triple negative disease had had fewer lines of treatment than did not triple negative. Patients who are HER2-negative generally receive between two and three lines of chemo therapy on average. Second line chemotherapy regimens varied. Capecitabine was the most common therapy (mono and combination) in all countries ranging from 36% (UK) to 40% (Germany). 2nd and 3rdmost common therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. In third line, the most commonly used agents were capecitabine (16%-44%) and vinorelbine (18%-26%). Eribulin was used in second line (3%-6%) and third line (11%-19%) in all countries except for Spain. Capecitabine is the most utilized chemotherapeutic agent in the second and third lines chemotherapy in Western Europe for HER2-negative patients. A variety of other regimens, primarily monotherapies, may also be used in later lines, including vinorelbine, gemcitabine, eribulin, and docetaxel." @default.
- W2033398373 created "2016-06-24" @default.
- W2033398373 creator A5000540201 @default.
- W2033398373 creator A5020942172 @default.
- W2033398373 creator A5064099470 @default.
- W2033398373 date "2014-11-01" @default.
- W2033398373 modified "2023-09-30" @default.
- W2033398373 title "Comparison of Epidemiology and Drug Treatment in HER2 Negative Metastatic Breast Cancer (MBC) in EU5" @default.
- W2033398373 doi "https://doi.org/10.1016/j.jval.2014.08.2189" @default.
- W2033398373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27202174" @default.
- W2033398373 hasPublicationYear "2014" @default.
- W2033398373 type Work @default.
- W2033398373 sameAs 2033398373 @default.
- W2033398373 citedByCount "4" @default.
- W2033398373 countsByYear W20333983732015 @default.
- W2033398373 countsByYear W20333983732019 @default.
- W2033398373 countsByYear W20333983732023 @default.
- W2033398373 crossrefType "journal-article" @default.
- W2033398373 hasAuthorship W2033398373A5000540201 @default.
- W2033398373 hasAuthorship W2033398373A5020942172 @default.
- W2033398373 hasAuthorship W2033398373A5064099470 @default.
- W2033398373 hasBestOaLocation W20333983731 @default.
- W2033398373 hasConcept C107130276 @default.
- W2033398373 hasConcept C120665830 @default.
- W2033398373 hasConcept C121332964 @default.
- W2033398373 hasConcept C121608353 @default.
- W2033398373 hasConcept C126322002 @default.
- W2033398373 hasConcept C143998085 @default.
- W2033398373 hasConcept C146357865 @default.
- W2033398373 hasConcept C151730666 @default.
- W2033398373 hasConcept C2775930923 @default.
- W2033398373 hasConcept C2776387010 @default.
- W2033398373 hasConcept C2776694085 @default.
- W2033398373 hasConcept C2777909004 @default.
- W2033398373 hasConcept C2778239845 @default.
- W2033398373 hasConcept C2778527826 @default.
- W2033398373 hasConcept C2779134260 @default.
- W2033398373 hasConcept C2780350996 @default.
- W2033398373 hasConcept C2781190966 @default.
- W2033398373 hasConcept C2908647359 @default.
- W2033398373 hasConcept C2992734768 @default.
- W2033398373 hasConcept C526805850 @default.
- W2033398373 hasConcept C530470458 @default.
- W2033398373 hasConcept C61511704 @default.
- W2033398373 hasConcept C71924100 @default.
- W2033398373 hasConcept C86803240 @default.
- W2033398373 hasConcept C99454951 @default.
- W2033398373 hasConceptScore W2033398373C107130276 @default.
- W2033398373 hasConceptScore W2033398373C120665830 @default.
- W2033398373 hasConceptScore W2033398373C121332964 @default.
- W2033398373 hasConceptScore W2033398373C121608353 @default.
- W2033398373 hasConceptScore W2033398373C126322002 @default.
- W2033398373 hasConceptScore W2033398373C143998085 @default.
- W2033398373 hasConceptScore W2033398373C146357865 @default.
- W2033398373 hasConceptScore W2033398373C151730666 @default.
- W2033398373 hasConceptScore W2033398373C2775930923 @default.
- W2033398373 hasConceptScore W2033398373C2776387010 @default.
- W2033398373 hasConceptScore W2033398373C2776694085 @default.
- W2033398373 hasConceptScore W2033398373C2777909004 @default.
- W2033398373 hasConceptScore W2033398373C2778239845 @default.
- W2033398373 hasConceptScore W2033398373C2778527826 @default.
- W2033398373 hasConceptScore W2033398373C2779134260 @default.
- W2033398373 hasConceptScore W2033398373C2780350996 @default.
- W2033398373 hasConceptScore W2033398373C2781190966 @default.
- W2033398373 hasConceptScore W2033398373C2908647359 @default.
- W2033398373 hasConceptScore W2033398373C2992734768 @default.
- W2033398373 hasConceptScore W2033398373C526805850 @default.
- W2033398373 hasConceptScore W2033398373C530470458 @default.
- W2033398373 hasConceptScore W2033398373C61511704 @default.
- W2033398373 hasConceptScore W2033398373C71924100 @default.
- W2033398373 hasConceptScore W2033398373C86803240 @default.
- W2033398373 hasConceptScore W2033398373C99454951 @default.
- W2033398373 hasIssue "7" @default.
- W2033398373 hasLocation W20333983731 @default.
- W2033398373 hasLocation W20333983732 @default.
- W2033398373 hasOpenAccess W2033398373 @default.
- W2033398373 hasPrimaryLocation W20333983731 @default.
- W2033398373 hasRelatedWork W1995504689 @default.
- W2033398373 hasRelatedWork W2059561061 @default.
- W2033398373 hasRelatedWork W2086140322 @default.
- W2033398373 hasRelatedWork W2147874203 @default.
- W2033398373 hasRelatedWork W2275049615 @default.
- W2033398373 hasRelatedWork W2338766826 @default.
- W2033398373 hasRelatedWork W2410831480 @default.
- W2033398373 hasRelatedWork W3108726652 @default.
- W2033398373 hasRelatedWork W4205733538 @default.
- W2033398373 hasRelatedWork W4252495345 @default.
- W2033398373 hasVolume "17" @default.
- W2033398373 isParatext "false" @default.
- W2033398373 isRetracted "false" @default.
- W2033398373 magId "2033398373" @default.
- W2033398373 workType "article" @default.